137 related articles for article (PubMed ID: 14577318)
21. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
24. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Kim YJ; Kim DW; Lee S; Kim YL; Hwang JY; Park YH; Kim HJ; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2004 Jan; 33(2):237-42. PubMed ID: 14628081
[TBL] [Abstract][Full Text] [Related]
26. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
27. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
28. [Early blastic transformation within a year of imatinib treatment in 2 cases of chronic myeloid leukemia].
Miyazaki K; Kon S; Watanabe T; Togano T; Ohsaka M; Suzuki Y; Danbara M; Horie R; Kanda Y; Maruta A; Higashihara M
Rinsho Ketsueki; 2007 Apr; 48(4):297-304. PubMed ID: 17515120
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
31. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
[TBL] [Abstract][Full Text] [Related]
32. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
33. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
34. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
Carella AM; Lerma E
Ann Hematol; 2007 Oct; 86(10):749-52. PubMed ID: 17576558
[TBL] [Abstract][Full Text] [Related]
35. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
[TBL] [Abstract][Full Text] [Related]
36. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
37. STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
Consoli U; Milone G; Guido G; Consoli C; Palumbo GA; Giustolisi R
Haematologica; 2002 Dec; 87(12):ECR37. PubMed ID: 12495908
[No Abstract] [Full Text] [Related]
38. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
[TBL] [Abstract][Full Text] [Related]
40. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]